Leqembi Set For Japan Launch After Twisty Pricing Process

Close Monitoring Under Conditional Approval

 
• By Lisa Takagi

Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.

Eisai has faced tough pricing negotiation with the MHLW for lecanemab, although both sides recognize its value.
Eisai faced tough Japan price negotiations for Leqembi, but both sides recognized value • Source: Shutterstock

More from Japan

More from Focus On Asia